Grandvista is an international enterprise group focusing on biomedical technology launched in 2019. It is jointly established by biomedical elites from Mainland China, the United States, Japan and Germany. Laboratories are set up in Texas, United States and Shanghai, Mainland China.
Its research team, with 30 years of experience, specialises in the research and development of cells, genes and new materials. Grandvista collaborates with the University of Leeds to research and develop new technologies in order to solve diseases, tissue regeneration and other problems through cell therapy. In addition, it develops new materials to apply and improve research and development efficiency.
At Grandvista, it encourages the community to enhance the quality of life of people and improve the development of biotechnology.
